New drug combo aims to stop rare kidney cancer from coming back
NCT ID NCT07225374
Summary
This study is testing if adding a drug called avelumab after standard chemotherapy can help keep cancer from returning in patients with a rare but aggressive type of cancer in the kidney or ureter. It will involve 48 adults who have already had surgery and completed chemotherapy with no current signs of cancer. The goal is to see if this maintenance therapy improves the time patients live without their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.